Riluzole Derivatives Inhibit Neuronal Activity-Regulated Glutamine Transport

Abstract

Researchers at Louisiana State University, New Orleans and the University of California, Davis have developed neuroprotective compounds that inhibit glutamine transport to reduce excitotoxic glutamate release, offering treatment for neurodegenerative diseases.

Full Description

This technology involves the development of SKA-378 compounds (Riluzole derivatives) that inhibit activity-regulated glutamine/methylaminoisobutyric acid transport to prevent glutamate-induced neuronal death. Tested in hippocampal slice cultures and animal models, these compounds show promising neuroprotective effects against ischemic and neurodegenerative injury. They may be combined with existing therapies such as NMDA receptor blockers to enhance efficacy.

Applications

• Treatment and prevention of neurodegenerative disorders like Alzheimer's disease. 
• Therapeutic intervention following cerebral ischemia and stroke. 
• Adjunct therapy in epilepsy to reduce neuronal damage. 
• Development of novel neuroprotective pharmaceuticals. 
• Use in combination drug regimens targeting excitotoxicity.

Features/Benefits

• Selective inhibition of glutamine/MeAIB transport linked to excitotoxicity. 
• Demonstrated neuroprotection in organotypic hippocampal cultures. 
• Potentially safer with favorable pharmacokinetic and toxicity profiles. 
• Compatible with combination therapies for enhanced effect. 
• Multiple administration routes available. 
• Prevents neuronal death driven by glutamate excitotoxicity. 
• Reduces damage from ischemic injury such as oxygen–glucose deprivation. 
• Slows or mitigates neurodegenerative progression including Alzheimer’s and epilepsy. 
• Overcomes limitations of current neuroprotective drugs by improving selectivity and efficacy.

Patent Status

Additional Patent Pending